Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13515920 | 0.82 | FKBP1A (0.35) | FKBP1AALDH1A1KDM4ETSHRMAPK1 | |
| SCHEMBL3529714 | 0.81 | FKBP1A (0.57) | FKBP1AMAPTALDH1A1KDM4ETSHR | |
| SCHEMBL11099628 | 0.81 | FKBP1A (0.57) | FKBP1AMAPTALDH1A1KDM4ETSHR | |
| SCHEMBL19171985 | 0.81 | FKBP1A (0.47) | FKBP1AMAPTALDH1A1KDM4ETSHR | |
| SCHEMBL3529712 | 0.81 | FKBP1A (0.57) | FKBP1AMAPTALDH1A1KDM4ETSHR | |
| SCHEMBL11490824 | 0.80 | FKBP1A (0.49) | FKBP1AMAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL11490823 | 0.80 | FKBP1A (0.49) | FKBP1AMAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL13601738 | 0.80 | FKBP1A (0.49) | FKBP1AMAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL4892941 | 0.80 | FKBP1A (0.49) | FKBP1AMAPTALDH1A1KDM4ETSHR | |
| SCHEMBL4454199 | 0.80 | FKBP1A (0.49) | FKBP1AMAPTALDH1A1KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041019-A1 | PROTEASE INHIBITORS | AMPLYX PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20120041019-A1 | PROTEASE INHIBITORS | AMPLYX PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20080227806-A1 | Novel Drugs for Dementia | AMERICAN LIFE SCIENCE PHARMACEUTICALS (US) | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227806-A1 | Novel Drugs for Dementia | CTSS, PRSS1, CBS | FKBP1A 1455/4885MAPT 172/4885ALDH1A1 2533/4885 |
| US-20120041019-A1 | PROTEASE INHIBITORS | SERPINB1, PREP, DNPEP | FKBP1A 1184/4885MAPT 1811/4885ALDH1A1 2740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.